203 related articles for article (PubMed ID: 30944005)
21. Comparable clinical outcomes in patients with HER2-mutant and EGFR-mutant lung adenocarcinomas.
Gow CH; Chang HT; Lim CK; Liu CY; Chen JS; Shih JY
Genes Chromosomes Cancer; 2017 May; 56(5):373-381. PubMed ID: 28063177
[TBL] [Abstract][Full Text] [Related]
22. [GRP78 expression in gastric cancer and its clinical significance].
Yang L; Yang SY; Ji JM; Cao YF; Ji CF; Ji JF; Xu WW; Wang JH
Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):837-42. PubMed ID: 24447482
[TBL] [Abstract][Full Text] [Related]
23. Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer.
van Beek EJAH; Hernandez JM; Goldman DA; Davis JL; McLaughlin K; Ripley RT; Kim TS; Tang LH; Hechtman JF; Zheng J; Capanu M; Schultz N; Hyman DM; Ladanyi M; Berger MF; Solit DB; Janjigian YY; Strong VE
Ann Surg Oncol; 2018 Jul; 25(7):2027-2033. PubMed ID: 29725898
[TBL] [Abstract][Full Text] [Related]
24. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
[TBL] [Abstract][Full Text] [Related]
25. Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.
Zhu Y; Sun Y; Hu S; Jiang Y; Yue J; Xue X; Yang L; Xue L
BMC Gastroenterol; 2017 Mar; 17(1):41. PubMed ID: 28292272
[TBL] [Abstract][Full Text] [Related]
26. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX.
Sehdev A; Gbolahan O; Hancock BA; Stanley M; Shahda S; Wan J; Wu HH; Radovich M; O'Neil BH
Clin Cancer Res; 2018 Dec; 24(24):6204-6211. PubMed ID: 30131383
[TBL] [Abstract][Full Text] [Related]
27. Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival.
Kang EJ; Im SA; Oh DY; Han SW; Kim JS; Choi IS; Kim JW; Kim YJ; Kim JH; Kim TY; Lee JS; Bang YJ; Lee KW
Gastric Cancer; 2013 Oct; 16(4):581-9. PubMed ID: 23266882
[TBL] [Abstract][Full Text] [Related]
28. The role of oxaliplatin in the adjuvant setting of different Lauren's type of gastric adenocarcinoma after D2 gastrectomy: a real-world study.
Cheng X; Yu S; Wang Y; Cui Y; Li W; Yu Y; Tang C; Jiang H; Ji Y; Sun Y; Wang X; Shen Z; Liu F; Liu TS
Gastric Cancer; 2019 May; 22(3):587-597. PubMed ID: 30426294
[TBL] [Abstract][Full Text] [Related]
29. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
Hecht JR; Bang YJ; Qin SK; Chung HC; Xu JM; Park JO; Jeziorski K; Shparyk Y; Hoff PM; Sobrero A; Salman P; Li J; Protsenko SA; Wainberg ZA; Buyse M; Afenjar K; Houé V; Garcia A; Kaneko T; Huang Y; Khan-Wasti S; Santillana S; Press MF; Slamon D
J Clin Oncol; 2016 Feb; 34(5):443-51. PubMed ID: 26628478
[TBL] [Abstract][Full Text] [Related]
30. Prognostic and predictive value of mismatch repair deficiency in gastric and gastroesophageal junction adenocarcinoma patients receiving neoadjuvant or adjuvant chemotherapy.
Li Z; Wang Y; Ying X; Zhang L; Gao X; Jia Y; Zhang L; Wu A; Su X; Ji J
J Surg Oncol; 2021 Dec; 124(8):1356-1364. PubMed ID: 34515995
[TBL] [Abstract][Full Text] [Related]
31. Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers.
Seo S; Park SJ; Ryu MH; Park SR; Ryoo BY; Park YS; Na YS; Lee CW; Lee JK; Kang YK
Oncotarget; 2017 May; 8(20):33844-33854. PubMed ID: 27802183
[TBL] [Abstract][Full Text] [Related]
32. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy.
Zhang M; Qi C; Wang Z; Chen H; Zhao X; Zhang X; Zhou Y; Gao C; Bai Y; Jia S; Ji J
J Mol Med (Berl); 2021 Sep; 99(9):1311-1321. PubMed ID: 34057552
[TBL] [Abstract][Full Text] [Related]
33. Blood neutrophil-lymphocyte ratio predicts survival in locally advanced cancer stomach treated with neoadjuvant chemotherapy FOLFOX 4.
el Aziz LM
Med Oncol; 2014 Dec; 31(12):311. PubMed ID: 25367855
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer.
Kim JW; Cho SY; Chae J; Kim JW; Kim TY; Lee KW; Oh DY; Bang YJ; Im SA
Cancer Res Treat; 2020 Oct; 52(4):1178-1187. PubMed ID: 32599979
[TBL] [Abstract][Full Text] [Related]
35. Non-randomized comparison between irinotecan plus mitomycin C and irinotecan alone in patients with advanced gastric cancer refractory to fluoropyrimidine and platinum.
Ueda A; Hosokawa A; Ogawa K; Yoshita H; Mihara H; Ando T; Kajiura S; Fujinami H; Nishikawa J; Minemura M; Terada M; Kobayashi T; Horikawa N; Yabushita K; Note M; Sugiyama T
Anticancer Res; 2013 Nov; 33(11):5107-11. PubMed ID: 24222156
[TBL] [Abstract][Full Text] [Related]
36. The prognostic significance of p21 and Her-2 gene expression and mutation/polymorphism in patients with gastric adenocarcinoma.
Ozen A; Kocak Z; Sipahi T; Oz-Puyan F; Cakina S; Saynak M; Ibis C; Karagol H
Med Oncol; 2013 Mar; 30(1):357. PubMed ID: 23275116
[TBL] [Abstract][Full Text] [Related]
37. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T
Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955
[TBL] [Abstract][Full Text] [Related]
38. Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France.
Guibert N; Barlesi F; Descourt R; Léna H; Besse B; Beau-Faller M; Mosser J; Pichon E; Merlio JP; Ouafik L; Guichard F; Mastroianni B; Moreau L; Wdowik A; Sabourin JC; Lemoine A; Missy P; Langlais A; Moro-Sibilot D; Mazières J
J Thorac Oncol; 2017 Jun; 12(6):963-973. PubMed ID: 28189832
[TBL] [Abstract][Full Text] [Related]
39. Retrospective analysis of adjuvant chemotherapy for curatively resected gastric cancer.
Deng W; Wang QW; Zhang XT; Lu M; Li J; Li Y; Gong JF; Zhou J; Lu ZH; Shen L
World J Gastroenterol; 2014 Mar; 20(12):3356-63. PubMed ID: 24696615
[TBL] [Abstract][Full Text] [Related]
40. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
Ott K; Rachakonda PS; Panzram B; Keller G; Lordick F; Becker K; Langer R; Buechler M; Hemminki K; Kumar R
Ann Surg Oncol; 2011 Sep; 18(9):2688-98. PubMed ID: 21347786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]